Seeking Alpha

Exidavnemab phase 2a study expanded to include MSA patients

STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...
Morningstar

Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

VALBY, Denmark, May 8, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) will present key pipeline data and patient perspectives from the phase II AMULET trial, investigating amlenetug as a potential ...
Nasdaq

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, July 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Healio

First patient dosed in second part of trial for AVD-104 to treat geographic atrophy

Please provide your email address to receive an email when new articles are posted on . Aviceda Therapeutics announced the dosing of the first patient in the second part of its phase 2/3 SIGLEC trial ...
MedPage Today

Treating Geographic Atrophy: Patient Selection Takes the Front Seat

Investigators in South Korea identified 84 older individuals with unilateral type 3 macular neovascularization at study entry that progressed to either GA or nAMD over the study period. During an ...